 |
|
|
| |
Improved Bone and Renal Safety at 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide: Results From 2 Phase 3 Studies in HBeAg-Positive and HBeAg-Negative Patients With Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
Presented at AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Calvin Q. Pan,1 Maurizia R. Brunetto,2 Aric Josun Hui,3 Rajiv Mehta,4 John F. Flaherty,5 Vithika Suri,5 George Wu,5 Anuj Gaggar,5 G. Mani Subramanian,5 Shuhei Nishiguchi,6 Hyung Joon Kim,7 Edward J. Gane,8 Wan-Long Chuang9
1Flushing Hospital Medical Center, Flushing, NY; 2Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 3Alice Ho Miu Ling Nethersole Hospital, Hong Kong; 4Nirmal Hospital Pvt Ltd, Surat, India; 5Gilead Sciences, Inc., Foster City, CA; 6Hyogo College of Medicine, Nishinomiya, Japan; 7Chung-Ang University Hospital, Seoul, South Korea; 8Auckland Clinical Studies Ltd, Auckland, New Zealand; 9Kaohsiung Medical University, Kaohsiung, Taiwan
References
1. Babusis D, et al. Mol Pharmaceutics 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Sax P, et al. Lancet 2015;385:2606-15; 6. Agarwal K, et al. EASL 2017, poster FRI-153; 7. Brunetto M, et al. EASL 2017, abstr PS-042; 8. Buti M, et al. Lancet Gastroenterol Hepatol 2016;1:196-206; 9. Chan HLY, et al. Lancet Gastroenterol Hepatol 2016;1:185-95; 10. Chan HLY, et al. EASL 2017, abstr PS-041.
|
| |
|
|
|
|
|
